All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MDS Hub spoke with Guillermo Garcia-Manero, MD Anderson Cancer Center, Houston, US. We asked, How have oral hypomethylating agents changed the management of MDS?
How have oral hypomethylating agents changed the management of MDS?
Garcia-Manero discusses hypomethylating agents in the management of MDS and acute myeloid leukemia (AML). He goes on to describe the challenges associated with hypomethylating agents, such as the route of administration often being intravenous/subcutaneous. Lastly, he talks about oral hypomethylating agents such as azacitidine and decitabine.
RIC allo-SCT vs HMA or best supportive care in older patients with high-risk MDS
The BMT CTN designed the phase II randomized trial 1102 (NCT02016781), to assess the benefits of reduced intensity conditioning (RIC) allo-SCT vs non-transplant...
Can changes in DNA methylation pattern predict the response to HMA in MDS?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Rafael Bejar, University of California San Diego, San Diego, US. We...
Subscribe to get the best content related to MDS delivered to your inbox